LY-320,135

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB 1 .

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB 1 . It was developed by Eli Lilly and Company in the 1990s.

LY-320,135 displays fairly good selectivity, with a binding affinity for CB 1 around 70x stronger than for CB 2 , but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB 1 antagonists act as inverse agonists at higher doses.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1341436302 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001341436302 · captured 2026-03-03 · ledger · version history

Cite this page as: encyclopegia.org, “LY-320,135”, snapshot enwiki-001341436302. https://encyclopegia.org/a/ly-320-135

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.